Allogene Therapeutics Stock Earnings Reports

Allogene emphasized conviction in its allogeneic CAR-T platform and outlined near-term clinical and financial milestones that matter to investors. Clinical: ALPHA3 (cema-cel) has been streamlined to a 2-arm randomized pivotal study (treatment after standard Flu/Cy lymphodepletion versus observation) with >50 active U.S./Canada sites (expansion to Australia and South Korea planned). A planned futility analysis focused on MRD conversion is on track for the first half of 2026; management highlighted a ~30% MRD conversion as a meaningful benchmark and believes a positive result could support a BLA path. ALLO-329 (dual CD19/CD70, Dagger technology) is enrolling a Phase I basket (Resolution) in lupus, myositis and scleroderma, with translational biomarker and early proof-of-concept data expected in H1 2026. TRAVERSE (ALLO-316) demonstrated durable responses in metastatic RCC with high CD70, supporting the Dagger approach for solid tumors. Operational: MRD testing is centralized (Foresight Diagnostics) to limit assay variability; site activation/enrollment has improved and is largely active. Financial: Q3 cash, cash equivalents and investments were $277.1M, providing a runway into H2 2027. Q3 R&D was $31.2M and G&A $13.7M; net loss was $41.4M ($0.19/share). 2025 guidance: cash burn ~ $150M and GAAP operating expenses ~ $230M (including ~$45M stock-based comp), excluding BD activity. Risks remain typical for biotech (trial, regulatory, timing, and execution), and management reiterated ongoing FDA interactions and uncertainty around CMC/regulatory requirements.